JPRN-UMIN000035158招募中1 期
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study - PC(UR-M) GEM/nab-PTX + MK615
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Active concomitant malignancy or history of another malignancy within the last 5years (2) Symptomatic brain metastasis (3) Severe infectious diseases (4) Subjects with the past history of Interstitial pneumonia or pulmonary fibrosis (5) Subjects with the past history of severe heart disease (6) Severe Paresthesia or Sensory disorder with motor dysfunction (7) Severe pleural effusion, ascites, or pericardial effusion (8) Subjects with the past history of severe diseases (kidney disease,liver disease, heart disease). (9) History of Radiation therapy for pancrearic cancer (10) Symptomatic brain metastases or Clinically suspected brain metastases. (11) Men/Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (12) Inappropriate to be enrolled in this study judged by the investigators
研究者
相似试验
招募中
1 期
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study (PC(UR-M) GEM/nab-PTX + MK615)pancreatic cancerJPRN-jRCTs061180074FUKUBA Nobuhiko35
已完成
不适用
efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancerunresectable pancreas cancerJPRN-UMIN000013206Yokohama City University Hospital Oncology
已完成
不适用
Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasisThe patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy.JPRN-UMIN000018878Study group of pancreatic cancer with peritoneal metastasis48
进行中（未招募）
1 期
Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma - GABRINOXEUCTR2012-003678-13-FRInstitut Régional de Cancerologie de Montpellier - Val d’Aurelle118
已完成
2 期
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24